The Michael J. Fox Foundationís Parkinsonís Disease Therapeutics Conference offers an unparalleled opportunity for Parkinsonís disease (PD) drug developers to hear the latest research results and build relationships that can lead to fruitful collaborations to benefit Parkinsonís patients.
ďNever before have there been more promising clues to what may serve as a target for Parkinsonís therapies,Ē said conference chair C. Warren Olanow, MD, of the Mount Sinai School of Medicine. ďThe Michael J. Fox Foundation is right in the middle of that, and this conference provides a golden opportunity to learn about these targets.Ē
The Foundationís seventh annual PD Therapeutics Conference will take place Thursday, October 24, in New York City. Held in partnership with the New York Academy of Sciences (NYAS), the event brings together approximately 250 research and business development professionals from academia and industry and showcases some of the most promising projects from MJFFís research portfolio.
ďOther funding supports research with preliminary data. Whatís been lacking is support for high-risk, high-reward projects,Ē Olanow said. ďThe Michael J. Fox Foundation is fostering great ideas, and the PD Therapeutics Conference is a chance to see where that has led.Ē
Novel advances in disease-modifying treatments, symptomatic therapies, and research tools and resources are highlighted through speaker presentations and a poster session at the NYAS headquarters. Donald E. Frail, PhD, from AstraZeneca PLC, and Eric Siemers, MD, of Eli Lilly and Company, will give ďHot TopicsĒ presentations on, respectively, drug repositioning and what the PD research community has learned from Alzheimerís disease trials.